2018 Union Meeting

IMPAACT at the 2018 Union World Conference on Lung Health

Members of the International Maternal Pediatric Adolescent AIDS Clinical Trials (IMPAACT) Network and IMPAACT Tuberculosis Scientific Committee (TB SC) presented several important outcomes, updates and proposals for the future TB research agenda at the 49th Union World Conference on Lung Health in The Hague, the Netherlands, on 24-27 October 2018.

P1078_CROI2018

Sharon Nachman, IMPAACT Network Chair, and Anneke Hesseling, TB SC and P1108 Chair, co-chaired a symposium on “Novel strategies to accelerate tuberculosis treatment trials in children”, with presentations from Tony Garcia-Prats, IMPAACT 2005 and IMPAACT 2020 protocol chair; Soyeon Kim, IMPAACT 2020 and PHOENIx statistician; Elin Svensson, P1108 and IMPAACT 2005 pharmacometrician; and Nishi Suryavanshi, BJMC Site Coordinator (CRS 31441). Amita Gupta, TB SC Vice-chair and P1078 Chair, presented on the “Impact of maternal isoniazid preventive therapy timing on acquisition of infant TB infection in the IMPAACT P1078/TB APPRISE trial” and “Managing tuberculosis in pregnancy”.  Renee Browning, DAIDS Medical Officer, co-chaired a workshop on “New imaging approaches for improving the diagnosis of paediatric intrathoracic TB and implications for research”, with an introduction by Patrick Jean-Philippe, Chief of the Maternal, Adolescent, and Pediatric Research Branch at DAIDS.

Additional presentations from IMPAACT members included:

  • Simon Schaaf, Vice-chair of P1108 and IMPAACT 2020, co-chaired a post-graduate course on “TB prevention in children in high TB burden settings: implementing the child contact management (CCM) care cascade”. Dr. Schaaf also presented on “Culture-confirmed tuberculosis in infants less than 3 months of age: clinical presentation and management”; “Injectable-free regimens, and the role of injectable agents, in the treatment of children with DR-TB”; and “Update on clinical and programmatic management of multidrug- and extensively drug-resistant TB (MDR-/XDR-TB)”.
  • Kelly Dooley, Vice-chair of IMPAACT 2001 and TB SC member, presented on the following during the conference:
    • “Preventive therapy in PLWH and the role of 3HP”, along with Salome Charalambous
    • “What is the right dose of pyrazinamide?”
    • “Pharmacokinetics, pharmacodynamics (PK/PD) and critical concentrations of tuberculosis medicines”
    • “Pharmacokinetics/pharmacodynamics of tuberculosis medicines: outcomes of a WHO expert consultation”
  • Anthony Garcia-Prats, IMPAACT 2005 and IMPAACT 2020 Chair, co-chaired a symposium on “Pharmacokinetics and pharmacodynamics (PK/PD) based dosing for children with tuberculosis” and presented on the following during the conference:
    • “Pharmacokinetics and pharmacodynamics in designing clinical trials in children”
    • “Pharmacokinetics, safety and optimal dosing of linezolid in children with multidrug-resistant tuberculosis”
    • “The current landscape of paediatric trials for the prevention and treatment of DS- and DR-TB: feeding the pipeline”
    • “Injectable-free regimens, and the role of injectable agents, in the treatment of children with DR-TB”, along with Simon Schaaf
    • “Pharmacokinetics, safety and dosing of levofloxacin 100 mg dispersible tablets in children exposed to multidrug-resistant tuberculosis”
  • Jyoti Mathad, IMPAACT 2001 Chair, presented on “Gestational diabetes suppresses the inflammatory response to M. tuberculosis in pregnant women in Pune, India.”
  • Lindsay McKenna, TB SC member, presented on “Ensuring children benefit from scientific progress: the paediatric tuberculosis pipeline report” and “Turning points for children with tuberculosis.”
  • Additional representation from TB SC Mentored Investigators included:
    • Sylvia LaCourse: Co-chaired oral abstract session on “Solutions to improved case finding and early treatment OR Find and treat”
    • Lisa Cranmer: Co-chaired oral abstract session on “Global approaches to child tuberculosis”. Dr. Cranmer also presented on “Immune reconstitution syndrome in hospitalized HIV-infected children starting ART” and “Virologic outcomes among Kenyan children receiving cART and TB therapy”
    • Jeffrey Tornheim: Presented on “How can we translate next generation sequencing data to shorten anti-tuberculosis treatment?”
    • Nicole Salazar-Austin: Presented on “Factors associated with completion of IPT in a cluster-randomized trial of symptom-based vs. TST-based screening of household TB contacts aged under 5 years”
    • Yaël Hirsch-Moverman: Co-chaired post-graduate course on “TB prevention in children in high TB burden settings: implementing the child contact management (CCM) care cascade”; oral abstract session on “The changing landscape of childhood tuberculosis”; and symposium on “Children exposed to tuberculosis have rights too! Improving child contact identification”. Dr. Hirsch-Moverman also presented on “Very low yield of child TB contacts to adult TB cases in Lesotho” and “Programmatic examples of child contact management from the field”
    • Elisabetta Walters: Chaired poster discussion session on “Child tuberculosis: leaping forward” and presented on “Mycobacterium tuberculosis detection from stool in young children using a novel centrifugation-free method with Xpert MTB/RIF”

Photos

 

Funded by the National Institute of Allergy and Infectious Diseases, the Eunice Kennedy Shriver National Institute of Child Health and Human Development, and the National Institute of Mental Health of the US National Institutes of Health, US Department of Health and Human Services.